Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial

•IMCL-9815 was a randomized phase 3 trial comparing radiotherapy (RT) ± cetuximab.•We previously reported that efficacy gains in IMCL-9815 arose irrespective of p16 status.•Regardless of p16 status, adding cetuximab to RT did not alter mucositis and dysphagia.•Similar findings were observed regarding the frequency of feeding tube use.